Literature DB >> 19453909

Oxidative stress and antioxidant status in patients with erectile dysfunction.

Alessandra Barassi1, Giovanni M Colpi, Guido Piediferro, Giada Dogliotti, Gian Vico Melzi D'Eril, Massimiliano M Corsi.   

Abstract

INTRODUCTION: Erectile dysfunction (ED) is increasingly recognized as a public health problem. The interaction between nitric oxide and reactive oxygen species is one of the important mechanisms implicated in the pathophysiological process of ED. Plasma contains various antioxidant components to prevent free-radical injury. AIM: The aim of this study was to determine and compare the oxidative and antioxidant status of peripheral venous blood in patients with ED of arteriogenic and non-arteriogenic origin.
METHODS: Oxidative stress and antioxidant status were assessed in 40 patients with ED and 20 healthy controls. MAIN OUTCOME MEASURES: Plasma reactive oxygen metabolite (ROM) concentrations were measured as an indicator of oxidative stress, and plasma total antioxidant status (TAS) to indicate antioxidant defense.
RESULTS: Plasma ROM concentrations were higher (349.75 +/- 53.35 standard deviation [SD] U.Carr vs. 285.43 +/- 25.58 U.Carr, P < 0.001) and plasma TAS lower (0.54 +/- 0.16 SD mmol/L vs. 0.94 +/- 0.28 SD mmol/L, P < 0.0001) in patients with arteriogenic ED in comparison to those in patients with non-arteriogenic ED. Plasma ROM and TAS in controls were not significantly different from those in non-arteriogenic ED. Conclusions. This observation may be useful to better understand and distinguish arteriogenic from non-arteriogenic ED using laboratory tests. In addition, our findings provide important support for an antioxidant therapy to try to correct oxidative stress in arteriogenic ED patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19453909     DOI: 10.1111/j.1743-6109.2009.01279.x

Source DB:  PubMed          Journal:  J Sex Med        ISSN: 1743-6095            Impact factor:   3.802


  6 in total

1.  Association between microvascular angina and erectile dsyfunction.

Authors:  S Demirkol; S Balta; U Kucuk; T Celik; Z Arslan; H Olgun Kucuk; M Unlu; U Cagdas Yuksel; S Samedli; M Yokusoglu; A Iyisoy; H Kursaklioglu
Journal:  Int J Impot Res       Date:  2013-12-19       Impact factor: 2.896

2.  p38 Mitogen-activated protein kinase (MAPK) increases arginase activity and contributes to endothelial dysfunction in corpora cavernosa from angiotensin-II-treated mice.

Authors:  Haroldo A Toque; Maritza J Romero; Rita C Tostes; Alia Shatanawi; Surabhi Chandra; Zidonia N Carneiro; Edward W Inscho; Robert Clinton Webb; Ruth B Caldwell; Robert William Caldwell
Journal:  J Sex Med       Date:  2010-08-30       Impact factor: 3.802

3.  Association between plasma fluorescent oxidation products and erectile dysfunction: A prospective study.

Authors:  Shuman Yang; Edward Giovannucci; Bruce Bracken; Shuk-Mei Ho; Tianying Wu
Journal:  BMC Urol       Date:  2015-08-14       Impact factor: 2.264

4.  Evaluation of high sensitive troponin in erectile dysfunction.

Authors:  Alessandra Barassi; Raffaele Pezzilli; Antonio Maria Morselli-Labate; Elena Dozio; Luca Massaccesi; Francesca Ghilardi; Clara Anna Linda Damele; Giovanni Maria Colpi; Gian Vico Melzi d'Eril; Massimiliano Marco Corsi Romanelli
Journal:  Dis Markers       Date:  2015-04-16       Impact factor: 3.434

5.  Levels of human erythrocyte membrane-bound and cytosolic glycohydrolases are associated with oxidative stress in erectile dysfunction patients.

Authors:  L Massaccesi; G V Melzi d'Eril; G M Colpi; G Tettamanti; G Goi; A Barassi
Journal:  Dis Markers       Date:  2014-08-05       Impact factor: 3.434

6.  Plasmatic Soluble Receptor for Advanced Glycation End Products as a New Oxidative Stress Biomarker in Patients with Prosthetic-Joint-Associated Infections?

Authors:  Luca Massaccesi; Barbara Bonomelli; Monica Gioia Marazzi; Lorenzo Drago; Massimiliano Marco Corsi Romanelli; Daniela Erba; Nadia Papini; Alessandra Barassi; Giancarlo Goi; Emanuela Galliera
Journal:  Dis Markers       Date:  2017-12-13       Impact factor: 3.434

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.